| Reporting Period | Filing Date | Average Time to Pay (days) | Paid within 30 days | Paid 31-60 days | Paid after 60 days | Not Paid within Terms |
|---|---|---|---|---|---|---|
| 01 Jul 2025 - 31 Dec 2025 | 27 Jan 2026 | 58 | 15% | 67% | 18% | 18% |
| 01 Jan 2025 - 30 Jun 2025 | 30 Jul 2025 | 59 | 19% | 68% | 13% | 13% |
| 01 Jul 2024 - 31 Dec 2024 | 28 Jan 2025 | 56 | 22% | 68% | 10% | 12% |
| 01 Jan 2024 - 30 Jun 2024 | 23 Jul 2024 | 64 | 20% | 67% | 13% | 17% |
| 01 Jul 2023 - 31 Dec 2023 | 09 Jan 2024 | 45 | 31% | 65% | 4% | 14% |
| 01 Jan 2023 - 30 Jun 2023 | 01 Aug 2023 | 60 | 24% | 59% | 17% | 25% |
| 01 Jul 2022 - 31 Dec 2022 | 31 Jan 2023 | 70 | 10% | 58% | 32% | 33% |
| 01 Jan 2022 - 30 Jun 2022 | 01 Aug 2022 | 57 | 12% | 59% | 29% | 4% |
| 01 Jul 2021 - 31 Dec 2021 | 31 Jan 2022 | 56 | 15% | 59% | 26% | 5% |
| 01 Jan 2021 - 30 Jun 2021 | 30 Jul 2021 | 51 | 12% | 61% | 27% | 4% |
| 01 Jul 2020 - 31 Dec 2020 | 21 Feb 2021 | 55 | 14% | 59% | 27% | 6% |
| 01 Jan 2020 - 30 Jun 2020 | 31 Jul 2020 | 59 | 9% | 63% | 28% | 25% |
| 01 Jul 2019 - 31 Dec 2019 | 04 Feb 2020 | 48 | 37% | 47% | 16% | 31% |
| 01 Jan 2019 - 30 Jun 2019 | 03 Sept 2019 | 53 | 41% | 43% | 16% | 31% |
This information is as reported by the business, and responses are in their own words.
Standard payment terms
There are no standard published payment terms for Lonza Biologics PLC, but most contracts are agreed with terms that allow for payment within 31-60 days
Were there any changes to the standard payment terms in the reporting period?
No information available
Any other information about payment terms
No additional information
Maximum contractual payment period agreed
90
Invoices which are incorrectly issued, or are issued in opposition to the previous contract agreements or arrangements are rejected by email to the vendor's correspondence address held within Lonza's systems; with accompanying instructions on what should be corrected for the invoice to be accepted. Lonza Biologics also operates a PO policy, where invoices without a Lonza PO are rejected unless specifically agreed in the contract with the vendor.
Has this business signed up to a code of conduct or standards on payment practices?
For example, signatories to The Prompt Payment Code must commit to paying 95% of their invoices within 60 days.
❌
Does this business offer e-invoicing in relation to qualifying contracts?
This is where suppliers can electronically submit and track invoices. It's not just allowing suppliers to email them an invoice.
❌
Does this business offer supply chain finance?
This is where a supplier who has submitted an invoice can be paid by a third-party finance provider earlier than the agreed payment date. The business would then pay the finance provider the invoiced sum.
❌
Under its payment practices and policies, can this business deduct sums from payments under qualifying contracts as a charge for remaining on a supplier list?
❌
During the reporting period, did the business deduct sums from payments as a charge for remaining on a supplier list?
No information available
Lonza Biologics PLC, registered in Slough, is part of the Lonza Group, a Swiss-founded contract development and manufacturing organisation (CDMO) serving the healthcare industry. The wider group works with biotech and pharmaceutical customers to develop and manufacture medicines, spanning mammalian biologics, small molecules, bioconjugates, mRNA, microbial and cell and gene technologies across more than 30 sites worldwide. Lonza Biologics PLC operates as a UK subsidiary within this group, associated with biologics development and manufacturing activity rather than being a separate standalone trading business. Group-wide, Lonza reported sales of CHF 6.5 billion in its most recent full year, reflecting the scale of the parent organisation rather than this individual registered entity.
Generated from the company's website and Companies House records. Sources: lonza.com · lonza.com